Renamed Lipoxen turns to Russia to derisk biotech development
This article was originally published in Scrip
Executive Summary
"We want to derisk our approach to biotech drug discovery." So says Scott Maguire, CEO of the UK firm formerly known as Lipoxen. The company has just undergone a complicated series of transactions and manoeuvres aimed at taking advantage of the Russian government's interest in investing in biotech. The company has established a business model that enables it to launch its products early into Russia or India before deciding which ones to develop further for North American and European markets.